Literature DB >> 33505944

Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases: The Heart of the Matter.

Stefan Chiriac1,2, Carol Stanciu2, Irina Girleanu1,2, Camelia Cojocariu1,2, Catalin Sfarti1,2, Ana-Maria Singeap1,2, Tudor Cuciureanu1, Laura Huiban1, Cristina Maria Muzica1, Sebastian Zenovia1, Robert Nastasa1, Anca Trifan1,2.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) has emerged as the most frequent cause of liver disease worldwide, comprising a plethora of conditions, ranging from steatosis to end-stage liver disease. Cardiovascular disease (CVD) has been associated with NAFLD and CVD-related events represent the main cause of death in patients with NAFLD, surpassing liver-related mortality. This association is not surprising as NAFLD has been considered a part of the metabolic syndrome and has been related to numerous CVD risk factors, namely, insulin resistance, abdominal obesity, dyslipidemia, hyperuricemia, chronic kidney disease, and type 2 diabetes. Moreover, both NAFLD and CVD present similar pathophysiological mechanisms, such as increased visceral adiposity, altered lipid metabolism, increased oxidative stress, and systemic inflammation that could explain their association. Whether NAFLD increases the risk for CVD or these diagnostic entities represent distinct manifestations of the metabolic syndrome has not yet been clarified. This review focuses on the relation between NAFLD and the spectrum of CVD, considering the pathophysiological mechanisms, risk factors, current evidence, and future directions.
Copyright © 2021 Stefan Chiriac et al.

Entities:  

Year:  2021        PMID: 33505944      PMCID: PMC7815392          DOI: 10.1155/2021/6696857

Source DB:  PubMed          Journal:  Can J Gastroenterol Hepatol        ISSN: 2291-2789


  111 in total

Review 1.  Gamma-glutamyltransferase is associated with incident vascular events independently of alcohol intake: analysis of the British Women's Heart and Health Study and Meta-Analysis.

Authors:  Abigail Fraser; Ross Harris; Naveed Sattar; Shah Ebrahim; George Davey Smith; D A Lawlor
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-10-11       Impact factor: 8.311

2.  Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.

Authors:  Mattias Ekstedt; Hannes Hagström; Patrik Nasr; Mats Fredrikson; Per Stål; Stergios Kechagias; Rolf Hultcrantz
Journal:  Hepatology       Date:  2015-03-23       Impact factor: 17.425

Review 3.  Non-alcoholic fatty liver disease - A global public health perspective.

Authors:  Zobair M Younossi
Journal:  J Hepatol       Date:  2018-11-09       Impact factor: 25.083

4.  Dynamics of intrapericardial and extrapericardial fat tissues during long-term, dietary-induced, moderate weight loss.

Authors:  Gal Tsaban; Arik Wolak; Hila Avni-Hassid; Yftach Gepner; Ilan Shelef; Yaakov Henkin; Dan Schwarzfuchs; Noa Cohen; Nitzan Bril; Michal Rein; Dana Serfaty; Shira Kenigsbuch; Lilac Tene; Hila Zelicha; Anat Yaskolka-Meir; Oded Komy; Avital Bilitzky; Yoash Chassidim; Uta Ceglarek; Michael Stumvoll; Matthias Blüher; Joachim Thiery; Dror Dicker; Assaf Rudich; Meir J Stampfer; Iris Shai
Journal:  Am J Clin Nutr       Date:  2017-08-16       Impact factor: 7.045

5.  Non-alcoholic fatty liver disease and progression of coronary artery calcium score: a retrospective cohort study.

Authors:  Dong Hyun Sinn; Danbee Kang; Yoosoo Chang; Seungho Ryu; Seonhye Gu; Hyunkyoung Kim; Donghyeong Seong; Soo Jin Cho; Byoung-Kee Yi; Hyung-Doo Park; Seung Woon Paik; Young Bin Song; Mariana Lazo; Joao A C Lima; Eliseo Guallar; Juhee Cho; Geum-Youn Gwak
Journal:  Gut       Date:  2016-09-06       Impact factor: 23.059

6.  Non-alcoholic fatty liver disease and the incidence of myocardial infarction: A cohort study.

Authors:  Dong Hyun Sinn; Danbee Kang; Yoosoo Chang; Seungho Ryu; Soo Jin Cho; Seung Woon Paik; Young Bin Song; Roberto Pastor-Barriuso; Eliseo Guallar; Juhee Cho; Geum-Youn Gwak
Journal:  J Gastroenterol Hepatol       Date:  2019-10-27       Impact factor: 4.029

7.  Effect of Nonalcoholic Fatty Liver Disease on In-Hospital and Long-Term Outcomes in Patients With ST-Segment Elevation Myocardial Infarction.

Authors:  Muhammed Keskin; Mert İlker Hayıroğlu; Ahmet Okan Uzun; Tolga Sinan Güvenç; Sinan Şahin; Ömer Kozan
Journal:  Am J Cardiol       Date:  2017-08-08       Impact factor: 2.778

8.  Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel.

Authors:  Jan Borén; M John Chapman; Ronald M Krauss; Chris J Packard; Jacob F Bentzon; Christoph J Binder; Mat J Daemen; Linda L Demer; Robert A Hegele; Stephen J Nicholls; Børge G Nordestgaard; Gerald F Watts; Eric Bruckert; Sergio Fazio; Brian A Ference; Ian Graham; Jay D Horton; Ulf Landmesser; Ulrich Laufs; Luis Masana; Gerard Pasterkamp; Frederick J Raal; Kausik K Ray; Heribert Schunkert; Marja-Riitta Taskinen; Bart van de Sluis; Olov Wiklund; Lale Tokgozoglu; Alberico L Catapano; Henry N Ginsberg
Journal:  Eur Heart J       Date:  2020-06-21       Impact factor: 29.983

9.  A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease.

Authors:  Cyrielle Caussy; Anupriya Tripathi; Greg Humphrey; Shirin Bassirian; Seema Singh; Claire Faulkner; Ricki Bettencourt; Emily Rizo; Lisa Richards; Zhenjiang Z Xu; Michael R Downes; Ronald M Evans; David A Brenner; Claude B Sirlin; Rob Knight; Rohit Loomba
Journal:  Nat Commun       Date:  2019-03-29       Impact factor: 14.919

View more
  6 in total

Review 1.  An Intricate Review on Nutritional and Analytical Profiling of Coconut, Flaxseed, Olive, and Sunflower Oil Blends.

Authors:  Roshina Rabail; Muhammad Asim Shabbir; Amna Sahar; Antoni Miecznikowski; Marek Kieliszek; Rana Muhammad Aadil
Journal:  Molecules       Date:  2021-11-26       Impact factor: 4.411

2.  The prognostic role of diabetes mellitus type 2 in the setting of hepatocellular carcinoma: a systematic review and meta-analysis.

Authors:  Anna Mrzljak; Maja Cigrovski Berković; Francesco Giovanardi; Quirino Lai
Journal:  Croat Med J       Date:  2022-04-30       Impact factor: 2.415

Review 3.  Ischemic Heart Disease and Liver Cirrhosis: Adding Insult to Injury.

Authors:  Irina Gîrleanu; Anca Trifan; Laura Huiban; Cristina Muzîca; Oana Cristina Petrea; Ana Maria Sîngeap; Camelia Cojocariu; Stefan Chiriac; Tudor Cuciureanu; Irina Iuliana Costache; Carol Stanciu
Journal:  Life (Basel)       Date:  2022-07-12

4.  Ethyl Acetate Fraction of Amomum villosum var. xanthioides Attenuates Hepatic Endoplasmic Reticulum Stress-Induced Non-Alcoholic Steatohepatitis via Improvement of Antioxidant Capacities.

Authors:  Jung-Hyo Cho; Jong-Suk Lee; Hyeong-Geug Kim; Hye Won Lee; Zhigang Fang; Hyeok-Hee Kwon; Dong Woon Kim; Chang-Min Lee; Jin-Woo Jeong
Journal:  Antioxidants (Basel)       Date:  2021-06-23

5.  Prognostic impact of liver fibrosis and steatosis by transient elastography for cardiovascular and mortality outcomes in individuals with nonalcoholic fatty liver disease and type 2 diabetes: the Rio de Janeiro Cohort Study.

Authors:  Claudia R L Cardoso; Cristiane A Villela-Nogueira; Nathalie C Leite; Gil F Salles
Journal:  Cardiovasc Diabetol       Date:  2021-09-24       Impact factor: 9.951

Review 6.  Heme Oxygenase-1: An Anti-Inflammatory Effector in Cardiovascular, Lung, and Related Metabolic Disorders.

Authors:  Stefan W Ryter
Journal:  Antioxidants (Basel)       Date:  2022-03-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.